Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
R Hammoud, DJ Drucker - Nature Reviews Endocrinology, 2023 - nature.com
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
JE Campbell, TD Müller, B Finan, RD DiMarchi… - Cell Metabolism, 2023 - cell.com
The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …
[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity
DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
The expanding incretin universe: from basic biology to clinical translation
DJ Drucker, JJ Holst - Diabetologia, 2023 - Springer
Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
R Bany Bakar, F Reimann, FM Gribble - … reviews Gastroenterology & …, 2023 - nature.com
Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …
New insights into the treatment of obesity
Obesity is a chronic, progressive and relapsing disease with a rising global prevalence
associated with increased morbidity and mortality and reduced quality of life. Treatment of …
associated with increased morbidity and mortality and reduced quality of life. Treatment of …
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
A Liskiewicz, A Khalil, D Liskiewicz, A Novikoff… - Nature …, 2023 - nature.com
The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1)
receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) …
receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) …
Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes
The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention
during the past three decades as a therapeutic target for the treatment of obesity and type 2 …
during the past three decades as a therapeutic target for the treatment of obesity and type 2 …
Advances in research on type 2 diabetes mellitus targets and therapeutic agents
J Su, Y Luo, S Hu, L Tang, S Ouyang - International Journal of Molecular …, 2023 - mdpi.com
Diabetes mellitus is a chronic multifaceted disease with multiple potential complications, the
treatment of which can only delay and prolong the terminal stage of the disease, ie, type 2 …
treatment of which can only delay and prolong the terminal stage of the disease, ie, type 2 …